Jabara Justin, Kiani Sara, Youn Alex, Feeley Brian
From the Department of Orthopaedic Surgery, University of California San Francisco (Jabara, Kiani, and Feeley), and the School of Medicine, University of California San Francisco, San Francisco, CA (Youn).
J Am Acad Orthop Surg. 2025 May 30;33(13):e731-e736. doi: 10.5435/JAAOS-D-25-00069.
Rotator cuff tear (RCT) management continues to represent a notable area of research given its widespread prevalence. Although current strategies of care focus on pain reduction and functional restoration, there has been an increasing amount of focus on the orthobiologics of RCTs in hopes of delivering more efficient, targeted therapies. Understanding these cellular mechanisms of rotator cuff injury outcomes is thus crucial in advancing biologic treatments; as such, this article first aims to summarize the orthobiologic mechanisms that underpin post-RCT tendon-bone healing and muscle degeneration. Next, we review the current strategies of biologic augmentation, including bone marrow stimulation, platelet-rich plasma, and mesenchymal stromal and stem cell therapy. Finally, we offer insights into the future of cell-based treatments, from harnessing extracellular vesicles to deliver biologic therapies to inducing promyogenic cellular differentiation at the site of injury.
鉴于肩袖撕裂(RCT)的广泛流行,其治疗仍然是一个值得关注的研究领域。尽管目前的治疗策略侧重于减轻疼痛和恢复功能,但人们越来越关注RCT的骨科生物制剂,以期提供更有效、更有针对性的治疗方法。因此,了解肩袖损伤结果的这些细胞机制对于推进生物治疗至关重要;为此,本文首先旨在总结支撑RCT后肌腱-骨愈合和肌肉退化的骨科生物机制。接下来,我们回顾了目前的生物增强策略,包括骨髓刺激、富血小板血浆以及间充质基质和干细胞治疗。最后,我们对基于细胞的治疗的未来提供见解,从利用细胞外囊泡递送生物疗法到在损伤部位诱导促肌细胞分化。